Escitalopram

Generic Name
Escitalopram
Brand Names
Cipralex, Lexapro
Drug Type
Small Molecule
Chemical Formula
C20H21FN2O
CAS Number
128196-01-0
Unique Ingredient Identifier
4O4S742ANY
Background

Escitalopram is a selective serotonin re-uptake inhibitor (SSRI) and the S-enantiomer of racemic citalopram. It is used to restore serotonergic function in the treatment of depression and anxiety. Escitalopram is approximately 150 times more potent than citalopram’s R-enantiomer and is responsible for the vast majority of citalopram’s clinical activity, with some evidence suggesting that the R-enantiomer of racemic citalopram actively dampens the activity of escitalopram rather than existing simply as an inactive enantiomer. Amongst SSRIs, escitalopram exerts the highest degree of selectivity for the serotonin transporter (SERT) relative to other off-targets which may explain its lower rates of adverse effects as compared to other agents in this class. Escitalopram also differentiates itself from other SSRIs via allosteric action on its target - this may be the mechanism responsible for its observed superior efficacy and faster onset compared to other SSRIs.

Indication

Escitalopram is indicated for the acute and maintenance treatment of major depressive disorder (MDD) in adults and pediatric patients 12 years old and older and for the acute treatment of generalized anxiety disorder (GAD) in adults and pediatric patients 7 years old and older. It is additionally indicated for symptomatic relief of obsessive-compulsive disorder (OCD) in Canada.

Associated Conditions
Anxiety, Generalized Anxiety Disorder, Major Depressive Disorder (MDD), Obsessive Compulsive Disorder (OCD)
Associated Therapies
-

Escitalopram in Patients With Generalized Anxiety Disorder

Phase 4
Completed
Conditions
Interventions
First Posted Date
2009-05-15
Last Posted Date
2011-06-10
Lead Sponsor
H. Lundbeck A/S
Target Recruit Count
30
Registration Number
NCT00902564
Locations
🇷🇺

RU001, Moscow, Russian Federation

MsFLASH-01: Escitalopram for Menopausal Symptoms in Midlife Women

First Posted Date
2009-05-07
Last Posted Date
2013-03-08
Lead Sponsor
Fred Hutchinson Cancer Center
Target Recruit Count
205
Registration Number
NCT00894543
Locations
🇺🇸

Northern California Kaiser, Division of Research, Oakland, California, United States

🇺🇸

Indiana University, Indianapolis, Indiana, United States

🇺🇸

University of Pennsylvania, Philadelphia, Pennsylvania, United States

and more 2 locations

Treatment Effects of Escitalopram (Lexapro®) on Generalized Anxiety Disorder in Patients With HIV and AIDS

Phase 3
Completed
Conditions
Interventions
First Posted Date
2009-04-24
Last Posted Date
2014-10-31
Lead Sponsor
Duke University
Target Recruit Count
30
Registration Number
NCT00887679
Locations
🇺🇸

Duke University Medical Center, Durham, North Carolina, United States

Preventing Depression in People Receiving Mechanical Ventilation in an Intensive Care Unit

Phase 4
Completed
Conditions
Interventions
First Posted Date
2009-03-31
Last Posted Date
2017-12-19
Lead Sponsor
University of Minnesota
Target Recruit Count
15
Registration Number
NCT00872027
Locations
🇺🇸

University of Minnesota Medical Center, Minneapolis, Minnesota, United States

Cognitive Behavioural Analysis System of Psychotherapy (CBASp) Versus Escitalopram in Chronic Depression

First Posted Date
2009-02-05
Last Posted Date
2010-06-30
Lead Sponsor
University Hospital Freiburg
Target Recruit Count
60
Registration Number
NCT00837564
Locations
🇩🇪

University of Bonn, Dept. of Psychiatry, Bonn, Germany

🇩🇪

University of Freiburg, Dept. of Psychiatry and Psychotherapy, Freiburg, Germany

Escitalopram (Lexapro) for the Treatment of Postpartum Depression

Phase 4
Completed
Conditions
Interventions
First Posted Date
2009-02-02
Last Posted Date
2014-08-06
Lead Sponsor
Massachusetts General Hospital
Target Recruit Count
7
Registration Number
NCT00833469
Locations
🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

Brain Effects of Escitalopram and Citalopram Using fMRI

First Posted Date
2009-01-21
Last Posted Date
2015-07-14
Lead Sponsor
Michael Henry, MD
Target Recruit Count
27
Registration Number
NCT00825825
Locations
🇺🇸

Steward St. Elizabeth's Medical Center, Boston, Massachusetts, United States

Quantitative Electroencephalogram (QEEG) Predictors of Response to Psychotherapy Versus Antidepressant Treatment in Depression

First Posted Date
2009-01-16
Last Posted Date
2018-01-05
Lead Sponsor
Massachusetts General Hospital
Target Recruit Count
39
Registration Number
NCT00824044
Locations
🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

An Eight-week Study of SSR411298 as Treatment for Major Depressive Disorder in Elderly Patients

First Posted Date
2009-01-14
Last Posted Date
2013-03-15
Lead Sponsor
Sanofi
Target Recruit Count
527
Registration Number
NCT00822744
Locations
🇺🇦

Sanofi-Aventis Administrative Office, Kiev, Ukraine

Eszopiclone Co-Administered With Escitalopram for Insomnia in Elderly Adults With Major Depressive Disorder

Phase 4
Completed
Conditions
Interventions
First Posted Date
2008-12-23
Last Posted Date
2012-10-03
Lead Sponsor
Lehigh Center for Clinical Research
Target Recruit Count
60
Registration Number
NCT00813735
Locations
🇺🇸

Lehigh Center for Clinical Research, Allentown, Pennsylvania, United States

© Copyright 2024. All Rights Reserved by MedPath